 Bradenton Herald | Pfizer's Vyndaqel Gets EC Approval for Transthyretin Familial Amyloid ... Genetic Engineering News It did, however, meet statistical significance in a predefined secondary analysis, which was designed to adjust for the impact of patient attrition due to liver transplantation. Following 18 months of treatment in a double-blind, placebo-controlled ... Pfizer's Vyndaqel(R) (tafamidis) First Therapy Approved in the European Union ... |
